Blueberry today announced the successful completion of an investment round raising a total of $1.75M from both UK and Swiss based investors. The investment will help take its 2 most advanced programs through to regulatory approval stage. Dr Mike Davies, Chief Medical Officer at Blueberry Therapeutics, commented that “this exciting investment now allows Blueberry to progress its most advanced nanotechnology program to clinical trial application (CTA) in EU and the second program, in onychomycosis, to IND stage in the USA before entering clinical trials early next year’.